Approximately 30% of AML cases with blasts carry an activating mutation in the FLT3 gene sequence, known as Flt3-ITD, which enhances blast proliferation and is associated with poor prognosis [79]. This evidence concerns the gene FLT3 and acute myeloid leukemia.